A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540
Active Not Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Univ of Alabama_Birmingham, Birmingham, Alabama +345 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Lifestyle Counseling and Medication for Adolescent Weight Management
NCT04873245
Active Not Recruiting
The prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe, scalable, and durable treatments without placing undue strain on the healthcare system. Clinical practice guidelines recommend behavioral interventions as the primary strategy for all ages and classes of obesity - moderate to severe. In 2017, the U.S. Preventive Services Task Fo... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/12/2025
Locations: University of Minnesota, Delaware Clinical Research Unit, Minneapolis, Minnesota
Conditions: Obesity, Childhood
Register for Updates
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372
Active Not Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: John Muir Physicians Network, Concord, California +118 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Register for Updates
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161
Active Not Recruiting
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Valley Clinical Trials, Inc., Northridge, California +48 locations
Conditions: Type 2 Diabetes
Register for Updates
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
NCT06499857
Not Yet Recruiting
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2025
Locations: The University of Arizona College of Medicine- Phoenix, Phoenix, Arizona +1 locations
Conditions: Overweight or Obesity, Atrial Fibrillation
Register for Updates
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Active Not Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +44 locations
Conditions: Obesity
Register for Updates
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
NCT06972992
Recruiting
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: Ascletis Clinical Site, San Antonio, Texas
Conditions: Chronic Weight Management
Register for Updates
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111
Not Yet Recruiting
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and inc... Read More
Gender:
FEMALE
Ages:
Between 45 years and 55 years
Trial Updated:
05/07/2025
Locations: University of Colorado-School of Medicine, Aurora, Colorado
Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Register for Updates
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
NCT05579249
Completed
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Nutrition Research Centre, Loma Linda, California
Conditions: Obesity
Register for Updates
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
NCT06299098
Recruiting
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/06/2025
Locations: Pinnacle Research Group, Anniston, Alabama +60 locations
Conditions: Obesity
Register for Updates
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726
Recruiting
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: UCLA Health, Los Angeles, California
Conditions: Obesity
Register for Updates
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
NCT06967389
Not Yet Recruiting
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/02/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor
Register for Updates